Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | MGMT | P16455 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13695971 | 1.00 | CRBN (0.38) | CRBNMEN1KMT2ASMN1; SMN2TTR | |
| SCHEMBL24795789 | 1.00 | CRBN (0.38) | CRBNMEN1KMT2ASMN1; SMN2TTR | |
| SCHEMBL31174135 | 1.00 | CRBN (0.38) | CRBNMEN1KMT2ASMN1; SMN2TTR | |
| SCHEMBL14922169 | 1.00 | CRBN (0.38) | CRBNMEN1KMT2ASMN1; SMN2TTR | |
| SCHEMBL18886281 | 0.88 | CRBN (0.41) | CRBNMEN1KMT2ASMN1; SMN2TTR | |
| SCHEMBL17282361 | 0.88 | CRBN (0.41) | CRBNMEN1KMT2ASMN1; SMN2TTR | |
| SCHEMBL19164024 | 0.88 | CRBN (0.38) | CRBNMEN1KMT2ASMN1; SMN2TTR | |
| SCHEMBL14922170 | 0.87 | CRBN (0.38) | CRBNMEN1KMT2ASMN1; SMN2TTR | |
| SCHEMBL23234313 | 0.87 | CRBN (0.38) | CRBNMEN1KMT2ASMN1; SMN2TTR | |
| SCHEMBL18886307 | 0.87 | CRBN (0.38) | CRBNMEN1KMT2ASMN1; SMN2TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186594-A1 | IL-18 POLYPEPTIDES MODIFIED WITH POLYMERS | BRIGHT PEAK THERAPEUTICS AG (CH) | 2025-06-12 | — | — | US | disclosed |
| WO-2025041095-A2 | IL-18 POLYPEPTIDES MODIFIED WITH POLYMERS | BRIGHT PEAK THERAPEUTICS AG (CH) | 2025-02-27 | — | — | WO | disclosed |
| US-20220280568-A1 | DUAL BISPECIFIC ANTIBODY COMPOUNDS AND USES THEREOF | CITY OF HOPE | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186594-A1 | IL-18 POLYPEPTIDES MODIFIED WITH POLYMERS | IL18, IL2, CXCL8 | CRBN 1763/4885MEN1 1217/4885KMT2A 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.